34.54

2.43% -0.86

After Hours: 34.35 -0.19 -0.55%

Vtv Therapeutics Inc (VTVT)

Overview News Price History Financials Discussions Forecast

Vtv Therapeutics Inc stock is traded at $34.54, with a volume of 29,903. It is down -2.43% in the last 24 hours and up +7.47% over the past month. vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Previous Close:

$35.40

Open:

$35.36

24h Volume:

29,903

Relative Volume:

0.58

Market Cap:

$136.04M

Revenue:

$36.84M

Net Income/Loss:

$-729.00K

P/E Ratio:

-37.39

EPS:

-0.9237

Net Cash Flow:

$-10.02M

1W Performance:

-4.77%

1M Performance:

+7.47%

6M Performance:

-19.14%

1Y Performance:

+129.20%

1-Day Range:

$34.23

$35.73

1-Week Range:

$34.23

$38.84

52-Week Range:

$14.00

$44.00

Vtv Therapeutics Inc Stock (VTVT) Company Profile

Name

Vtv Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

336-841-0300

Address

3980 PREMIER DR, HIGH POINT, NC

Employee

Twitter

@vTvTherapeutics

Next Earnings Date

2026-08-11

Latest SEC Filings

VTVT's Discussions on Twitter

Compare VTVT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTVT Vtv Therapeutics Inc	34.54	148.29M	36.84M	-729.00K	-10.02M	-0.9237
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Initiated	Evercore ISI	Outperform
Jan-23-26	Initiated	Roth Capital	Buy
Jan-05-26	Initiated	TD Cowen	Buy
Nov-19-25	Initiated	BTIG Research	Buy
May-30-19	Initiated	H.C. Wainwright	Buy
Apr-10-18	Downgrade	Stifel	Buy → Hold
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-08-18	Initiated	Northland Capital	Outperform
Sep-26-16	Initiated	H.C. Wainwright	Buy
Sep-04-15	Initiated	Canaccord Genuity	Buy
Aug-24-15	Initiated	Piper Jaffray	Overweight
Aug-24-15	Initiated	Stifel	Buy

View All

Vtv Therapeutics Inc Stock (VTVT) Latest News

Jun 30, 2026

Trading the Move, Not the Narrative: (VTVT) Edition - Stock Traders Daily

Jun 30, 2026

Rodman & Renshaw initiates vTv Therapeutics stock with buy rating - Investing.com

Jun 30, 2026

Enterprise value to EBITDA forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView

Jun 30, 2026

Jun 29, 2026

6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds - Stock Titan

Jun 29, 2026

vTv Therapeutics Shareholders Approve Directors, Question Executive Pay - TipRanks

Jun 29, 2026

Form 4 vTv Therapeutics Inc For: 29 June By Investing.com - Investing.com Canada

Jun 29, 2026

[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan

Jun 29, 2026

vTv Therapeutics (VTVT) director granted 6,000 stock options at $35.08 - Stock Titan

Jun 29, 2026

Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant - Stock Titan

Jun 29, 2026

Director at vTv Therapeutics (VTVT) receives 6,000 stock options grant - Stock Titan

Jun 29, 2026

Director Fahed Al-Marzooqi (VTVT) granted 6,000 vTv Therapeutics stock options - Stock Titan

Jun 29, 2026

Enterprise value to revenue forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView

Jun 29, 2026

VTVT: Directors and auditor were approved, but executive compensation was not - TradingView

Jun 26, 2026

vTv Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 26, 2026

vTv Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VTVT) - TradingView

Jun 26, 2026

Jun 25, 2026

VTVT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026